Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism
Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism. Topline results are expected in mid-December 2026. * Previously reported results showed seven of the first eight participants met the primary endpoint; all seven stopped intravenous glucose treatment. No